mmm
What the results are …
Link to additional publications
Pericytes in the gut
Ramirez M, Pell N, Mejias M, Fernandez M
Co-first authors: Marta Ramirez and Nuria Pell
Corresponding author: Mercedes Fernandez
Advances in Experimental Medicine and Biology, “Biology of Pericytes: Development, Homeostasis and Disease”. Springer (ISSN:0065-2598)(in press)
Placental growth factor: New treatment target bringing hope in hepatopulmonary syndrome
Fernandez M
Corresponding author: Mercedes Fernandez
Hepatology 2018; 68:404-407
Invited Editorial
Maillo C, Martin J, Sebastian D, Hernandez-Alvarez M, Garcia-Rocha M, Reina O, Zorzano A, Fernandez M, Mendez R
Co-corresponding authors: Raul Mendez and Mercedes Fernandez
Nature Cell Biology 2017; 19:94-105
Comment on this paper: Moore PC & Oakes SA. CPEB4 links the clock and the UPR to protect the liver. Nature Cell Biology (2017);19:79-81. Comment
This paper received the Award to the Best Scientific Publication (Year 2018) from the Spanish Association Against Cancer (AECC)
Therapeutic siRNA targeting endothelial KDR decreases portosystemic collateralization in portal hypertension
Gallego J, Garcia-Pras E, Mejias M, Pell N, Schaeper U, Fernandez M
Co-first authors: Javier Gallego and Ester Garcia-Pras
Corresponding author: Mercedes Fernandez
Scientific Reports 2017; 7:14791-14806 PubMed Springer Nature SharedIt
Role and therapeutic potential of vascular stem/progenitor cells in pathological neovascularisation during chronic portal hypertension
Garcia-Pras E, Gallego J, Coch L, Mejias M, Fernandez-Miranda G, Pardal R, Bosch J, Mendez R, Fernandez M
Corresponding author: Mercedes Fernandez
Gut 2017; 66:1306-1320 PubMed
Gastroesophageal varices
Fernandez M, Abraldes JG
Corresponding author: Mercedes Fernandez
In: Liver Pathophysiology: Therapies & Antioxidants 2017; Ed. Muriel P, Academic Press, Elsevier (ISBN: 978-0-12-804274-8)
Invited Review
Sequential functions of CPEB1 and CPEB4 regulate pathologic expression of VEGF and angiogenesis in chronic liver disease
Calderone V, Gallego J, Fernandez-Miranda G, Garcia-Pras E, Maillo C, Berzigotti A, Mejias M, Bava FA, Angulo-Urarte A, Graupera M, Navarro P, Bosch J, Fernandez M, Mendez R
Co-first authors: Vittorio Calderone and Javier Gallego
Co-corresponding authors: Raul Mendez and Mercedes Fernandez
Gastroenterology 2016;150:982-997 PubMed
Pathogenesis of portal hypertension: Extrahepatic mechanisms
Fernandez M, Mejias M, Garcia-Pras E, Gallego J, Pell N, Ramirez M, Naranjo-Suarez S, Barrachina-Catala A
Corresponding author: Mercedes Fernandez
Current Hepatology Reports 2016;15:199-207
Invited Review
Molecular pathophysiology of portal hypertension
Fernandez M
Corresponding author: Mercedes Fernandez
Hepatology 2015; 61:1406-1415 PubMed
Invited Review
Antiangiogenic and antifibrogenic activity of pigment epithelium-derived factor (PEDF) in bile duct-ligated portal hypertensive rats
Mejias M, Coch L, Berzigotti A, Garcia-Pras E, Gallego J, Bosch J, Fernandez M
Corresponding author: Mercedes Fernandez
Gut 2015; 64:657-666 PubMed
Editorial devoted to this article: Vespasiani-Gentilucci U, Rombouts K. Boosting pigment epithelial-derived factor: a promising approach for the treatment of early portal hypertension. Gut (2015) 64:523-524 Editorial
Disruption of negative feedback loop between vasohibin-1 and vascular endothelial growth factor decreases portal pressure, angiogenesis, and fibrosis in cirrhotic rats
Coch L, Mejias M, Berzigotti A, Garcia-Pras E, Gallego J, Bosch J, Mendez R, Fernandez M
Corresponding author: Mercedes Fernandez
Hepatology 2014; 60:633-647 PubMed
Editorial devoted to this article: Chatterjee S. Reversal of vasohibin-driven negative feedback loop of vascular endothelial growth factor/angiogenesis axis promises a novel antifibrotic therapeutic strategy for liver diseases. Hepatology (2014) 60:458-460 Editorial
Hepatology Highlights devoted to this article: Dufour JF. After vasopressin comes vasohibin. Hepatology (2014) 60:447 Highlights
Effects of the combined administration of propranolol plus sorafenib on portal hypertension in cirrhotic rats
D’Amico M, Mejias M, Garcia-Pras E, Abraldes JG, Garcia-Pagan JC, Fernandez M, Bosch J
American Journal of Physiology 2012;302:G1191-G1198 PubMed
Relevance of the mTOR signaling pathway in the pathophysiology of splenomegaly in rats with chronic portal hypertension
Mejias M, Garcia-Pras E, Gallego J, Mendez R, Bosch J, Fernandez M
Corresponding author: Mercedes Fernandez
Journal of Hepatology 2011; 52:529-539 PubMed
Hepatic endothelial dysfunction and abnormal angiogenesis: New targets in the treatment of portal hypertension
Bosch J, Abraldes JG, Fernandez M, Garcia-Pagan JC
Journal of Hepatology 2010; 53:558-567 PubMed
Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats
Mejias M, Garcia-Pras E, Tiani C, Miquel R, Bosch J, Fernandez M
Corresponding author: Mercedes Fernandez
Hepatology 2009;49:1245-1256 PubMed
Editorial devoted to this article: Shah VH, Bruix J. Antiangiogenic therapy: not just for cancer anymore? Hepatology (2009) 49:1066-1068 Editorial
Apelin signaling modulates splanchnic angiogenesis and portosystemic collateral vessel formation in rats with portal hypertension
Tiani C, Garcia-Pras E, Mejias M, de Gottardi A, Berzigotti A, Bosch J, Fernandez M
Corresponding author: Mercedes Fernandez
Journal of Hepatology 2009; 50:296-305 PubMed
Angiogenesis in liver disease
Fernandez M, Semela D, Bruix J, Colle I, Pinzani M, Bosch J
Journal of Hepatology 2009; 50:604-620 PubMed
As of September 2018, this “Highly Cited Paper” received enough citations (285) to place it in the top 1% of its academic field based on a highly cited threshold for the field and publications year. Data from Essential Science Indicators.
Impacto de los inhibidores de la angiogénesis en el tratamiento de la hipertensión portal
Fernandez M
Corresponding author: Mercedes Fernandez
Gastroenterología y Hepatología Continuada 2009;8:312-317
Invited Review
The somatostatin analogue octreotide inhibits angiogenesis in the earliest, but not in advanced, stages of portal hypertension in rats
Mejias M, Garcia-Pras E, Tiani C, Bosch J, Fernandez M
Corresponding author: Mercedes Fernandez
Journal of Cellular and Molecular Medicine 2008;12: 1690-1699 PubMed
Role of angiogenesis in portal hypertension
Fernandez M, Mejias M, Garcia-Pras E, Bosch J
Corresponding author: Mercedes Fernandez
In: Liver Cirrhosis: From Pathophysiology to Disease Management 2008; Edited by: Bosch J, Burroughs AK, Lammert F, Sauerbruch T, Lebrec D. Springuer, Dordrecht, The Netherlands. Volume 162, pages 112-129
Invited Review
Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats
Fernandez M, Mejias M, Garcia-Pras E, Mendez R, Garcia-Pagan JC, Bosch J
Corresponding author: Mercedes Fernandez
Hepatology 2007;46:1208-1217 PubMed
This paper received the Award to the Best Publication in Hepatology Research (Year 2007), from the Spanish Association for the Study of the Liver
NAD(P)H oxidase modulates angiogenesis and the development of portosystemic collaterals and splanchnic hyperaemia in portal hypertensive rats
Angermayr B, Fernandez M, Mejias M, Gracia-Sancho J, Garcia-Pagan JC, Bosch J
Corresponding author: Mercedes Fernandez
Gut 2007;56:560-564 PubMed
Heme oxygenase attenuates oxidative stress and inflammation, and increases VEGF expression in portal hypertensive rats
Angermayr B, Mejias M, Gracia-Sancho J, Garcia-Pagan JC, Bosch J, Fernandez M
Corresponding author: Mercedes Fernandez
Journal of Hepatology (2006) 44:1033-1039 PubMed
Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats
Fernandez M, Mejias M, Angermayr B, Garcia-Pagan JC, Rodes J, Bosch J
Corresponding author: Mercedes Fernandez
Journal of Hepatology (2005) 43:98-103 PubMed
Editorial devoted to this article: Moreau R. “VEGF-induced angiogenesis drives collateral circulation in portal hypertension”. J Hepatol 2005;43:6-8 Editorial
Heme oxygenase in portal hypertension and liver disease
Lambrecht RW, Fernandez M, Shan Y, Bonkovsky HL
In: Ascites and Renal Dysfunction in Liver Disease. Pathogenesis, diagnosis and treatment (2005). Edited by: Gines P, Arroyo V, Rodes J, Schrier RW. Blackwell Publishing Ltd, Oxford, United Kingdom. Pg. 125-136
Invited Review
Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice
Fernandez M, Vizzutti F, Garcia-Pagan JC, Rodes J, Bosch J
Corresponding author: Mercedes Fernandez
Gastroenterology (2004) 126:886-894 PubMed
Vascular endothelial growth factor increases heme oxygenase-1 expression in the chicken embryo chorioallantoic membrane
Fernandez M, Bonkovsky HL
Corresponding author: Mercedes Fernandez
British Journal of Pharmacology (2003) 139:634-640 PubMed
Increased heme oxygenase activity in splanchnic organs from portal hypertensive rats: Role in modulating mesenteric vascular reactivity
Fernandez M, Lambrecht RW, Bonkovsky HL
Corresponding author: Mercedes Fernandez
Journal of Hepatology (2001) 34:812-817 PubMed
Editorial devoted to this article: Moreau R. Heme oxygenase: protective enzyme or portal hypertensive molecule?. Journal of Hepatology (2001) 34:936-939 Editorial
Increased heme oxygenase-1 gene expression in liver cells and splanchnic organs from portal hypertensive rats
Fernandez M, Bonkovsky HL
Corresponding author: Mercedes Fernandez
Hepatology (1999) 29:1672-1679 PubMed